Hemophilia Treatment Market Scope And Analysis

Report Code : TIPRE00008241
Category : Pharmaceuticals

No. of Pages : 150

Buy Now

Hemophilia Treatment Market Analysis, Scope, and Growth by 2031

Buy Now

Hemophilia Treatment Market Report Scope

Report Attribute	Details
Market size in 2021	US$ 14.44 Billion
Market Size by 2031	US$ 23.53 Billion
Global CAGR (2023 - 2031)	5.1%
Historical Data	2021-2022
Forecast period	2023-2031
Segments Covered	By Product Plasma Derived Coagulation Factor Concentrates Recombinant Coagulation Factor Concentrates Desmopressin Antifibrinolytic Agents By Disease Hemophilia A Hemophilia B Hemophilia C By Treatment Type On-demand Prophylaxis By Therapy Replacement Therapy ITI Therapy Gene Therapy Antibody Therapy
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	Bayer AG Sanofi F Hoffmann la Roche Ltd Kedrion S P A CSL Limited Biotest AG Pfizer Inc Novo Nordisk A S Octapharma AG Baxter International Inc

Hemophilia Treatment Market News and Recent Developments

The hemophilia treatment market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. The following is a list of developments in the market for hemophilia treatment:

The Japanese Ministry of Health, Labor, and Welfare (MHLW) has granted marketing authorization for ALTUVIIIO [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein], a first-in-class, high-sustained factor VIII replacement therapy. ALTUVIIIO is indicated for control of bleeding tendency in patients with hemophilia A (factor VIII deficiency). ALTUVIIIO was also recently approved by the Taiwan Food and Drug Administration for treatment of adults and children with hemophilia A on August 31, 2023. (Source: Sanofi, Press Release, 2023)
Takeda Pharmaceutical Company Limited (“Takeda”) announced the U.S. availability of myPKFiT for ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], a web-based software and mobile application that is the first and only pharmacokinetic (PK)-dosing software approved by the U.S. Food and Drug Administration (FDA) for hemophilia A patients 12 and older and weighing at least 29 kg treated with ADYNOVATE. (Source: Takeda Pharmaceutical Company Limited, Press Release, 2020)

Hemophilia Treatment Market Report Coverage and Deliverables

The “Hemophilia Treatment Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:

Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
Market dynamics such as drivers, restraints, and key opportunities
Key future trends
Detailed PEST/Porter’s Five Forces and SWOT analysis
Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments
Detailed company profiles